ALKERMES | ALKS - 股票

金融业

USD

USD 4.39B

现金及等价物

USD 511.53M

USD 120.7M

USD 1.52B

USD 662.09M

USD 1.58B

股息收益率

0

USD -65.93M

USD 139.22M

1.8K

EPS每股收益

USD 0

股本和储备

USD 1.81B

USD 375.31M

债务利息支出

USD 25.93M

USD 8.54M

USD 1.48B

USD 7.77B

USD 501K

USD 1.81B

USD -65.93M

普通股股本

USD 167.54M

135.81

USD -61.93M

USD 496.01M

销售和管理费用

USD 196.64M

USD 298.96M

贸易债权人

USD 142.86M

应收帐款人

USD 456.48M

	股票	更改		日
AbbVie	USD 5.13B		78M	2026-06
Acadia Pharmaceuticals	USD 108.67M		77.1M	2026-06
ALKERMES	USD 298.96M		37.75M	2026-06
Amgen	USD 6.22B		34M	2026-06
Biogen	USD 2.38B		435.3M	2026-06
BioMarin Pharmaceutical	USD 1.78B		509.3M	2026-06
Bristol-Myers Squibb	USD 2.74B		19M	2026-06
Coherus Biosciences	USD 5.67M		842K	2026-06
Eli Lilly	USD 16.79B		2.26B	2026-06
Gilead Sciences	USD 1.91B		140M	2026-03
Heron Therapeutics	USD 54.57M		2.33M	2022-12
Ionis Pharmaceuticals	USD 50.83M		45.28M	2026-06
J&J	USD 15.14B		561M	2026-06
Merck	USD 6.21B		272M	2026-06
Nektar Therapeutics	USD 14.46M		1.78M	2024-06
Neurocrine Biosciences	USD 104.2M		39.7M	2026-06
Otsuka Holdings	JPY 374.32B		23.79B	2025-12
Pfizer	USD 9.94B		722M	2026-06
Regeneron Pharmaceuticals	USD 3.08B		19.3M	2026-06
Vertex Pharmaceuticals	USD 1.77B		1.6M	2026-06